Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na

Journal of Infectious Diseases

Volumn 176, Issue 4, 1997, Pages 884-891

  Brandt, Christian ^b   Power, Ultan F ^b   Plotnicky Gilquin, Hélène ^b   Huss, Thierry ^b   Nguyen, Thien ^b   Lambert, Paul Henri ^b   Binz, Hans ^b   Siegrist, Claire Anne ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; HYBRID PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION; VIRUS INFECTION;

EID: 0030820061     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/516503     Document Type: Article

References (13)

1. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race, and sex. Am J Epidemiol 1973;98:289-300.
2. Martin AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral infection among pediatric inpatients over a six year period in northeast England. Lancet 1978;2:1035-8.
3. Hall CB, Kopelman AE, Douglas RG, et al. Neonatal respiratory syncytial virus infection. N Engl J Med 1979;300:393-6.
4. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J Pediatr 1981;140:543-6.
5. Green M, Brayer AF, Schenkman KA, Wald ER. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J 1989;8:601-5.
6. Cane PA, Pringle CR. Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein. J Virol 1995;69:2918-25.
7. Garcia O, Martin M, Dopazo J, et al. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994;68:5448-59.
8. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991;65:5425-34.
9. Chin J, Magoffin RL, Shearer LA, Schiebte JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449-63.
10. Kim HW, Leikin SL, Arrobio JO, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to RSV induced by inactivated vaccine or by infection. Pedriatr Res 1976;10:75-8.
11. Åkerlind-Stopner B, Utter G, Mufson MA, Orvell C, Lerner RA, Norrby E. A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop. J Virol 1990;64:5143-8.
12. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 1991;185:749-57.
13. Nygren PÅ, Flodby P, Andersson R, Wigzell H, Uhlén M. In: Chanock RM, Brown F, Ginsberg HS, Lerner RA, eds. Vaccines 91, modern approaches to vaccine development. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1991:363-8.